Search CORE

41 research outputs found

RICORS2040 : The need for collaborative research in chronic kidney disease

Author: Agilar M.A.
Agudo C.P.B.
Aguiar P.V.A.
Albadalejo López Santiago
Alonso J.
Alvarez-Llamas G.
Amador M.M.
Andujar A.M.
Arduan A.O.
Arellano Armisen Manuel
Arenas M.D.
Arias B.P.
Arias L.M.
Ars Elisabet
Bajo M.J.R.
Balboa N.E.
Baltanas R.L.
Bardaji A.M.
Barja L.M.C.
Barreiro A.S.
Barreiro J.M.L.
Barrera C.B.
Barrio M.C.
Bartolomé M.F.
Basilio L.C.
Becerra B.R.
Belmonte A.A.
Benito-Hernández A.
Benítez P.R.
Berenguer Marina
Bermejo M.L.G.
Bermúdez A.I.R.
Betsabé I.T.
Blanch N.L.
Blasco Pelicano Miquel
Boillos A.B.
Bonet L.A.
Bonilla J.L.A.
Boque E.C.
Bordignondraibe J.
Borra J.M.
Bravo M.Á.G.
Caballero A.
Cabello M.
Cabrales C.A.
Cabrera B.E.
Cabrera C.V.
Cabrera M.L.
Cachaza N.C.
Calabia E.R.
Calvo I.F.
Canal Girol Cristina
Cannata Andía J.B.
Carrasco A.G.
Carro B.M.
Casanova Paso A.G.
Caso C.
Caso M.D.L.Á.C.
Castañeda J.R.M.
Castelao A.M.
Castiñeira J.R.V.
Catalina M.C.
Cenarruzabeitia N.V.
Centenera G.O.
Chamond M.R.R.
Cobo Caso M.D.L.A.
Correa P.S.
Corte M.D.C.D.
Cuarental L.
Cucchiari David
Córdoba-David G.
de Arriba Gabriel
De Gracia Guindo M.D.C.
De La Iglesia A.M.B.
De Lamo V.M.
De Los Angeles M.
De Mier M.V.P.R.
De Miguel P.M.
De Montaner E.R.A.
De Ona J.G.
de Sequera Patricia
Delgado J.B.
Delgado N.P.
Diekmann F.
Diezhandin M.G.
Donate-Correa J.
Díaz Encarnación Montserrat Mercedes
Díaz M.N.
Díaz M.N.
Eijo A.C.
Enriquez M.C.
Escribano T.C.
Expósito L.M.
Facundo Carme
Fajardo J.P.T.
Favero C.
Fernandez Fresnedo Gema
Fernández Rodríguez M.A.
Fernández A.L.
Fernández A.S.
Fernández M.P.
Fernández N.G.
Fernández-Fernández B.
Fondevila Campo Constantino
Font M.X.
Fontan F.C.
Fontan M.P.
Fontecha-Barriuso M.
Fuentes M.D.C.R.
Fuentes R.W.
Furlano Monica
G. Cosio M. Dolores
Gallardo M.L.
Gallego Zurro Daniel
Gallego R.H.
Galán A.D.
Gamboa M.J.R.
Gamboa M.R.
Garcia Rebollo M.S.
García E.C.
García E.R.
García L.Á.
García M.E.G.
García M.R.
García P.G.
García S.P.
García-Jiménez J.
García-Menéndez E.
Garrido R.G.D.M.
Garrido R.S.J.
Garriel M.P.
Garrit J.M.C.
Genis B.B.
Gigarrán-Guldris S.
Gilsanz G.D.P.
Goicoechea Marian
González A.O.
González A.Á.
González L.R.
González M.G.
González M.O.
González M.V.
González M.Á.G.N.
González O.C.
González V.P.
González Á.G.
Gorostidi Pérez Manuel
Guerrero-Mauvecin J.
Guillen M.A.
Guirado Luis
Gutiérrez Porras Inmaculada
Gutiérrez R.L.
Gómez Gómez Clemente
Gómez Ruiz Josefa
Gómez A.P.
Gómez J.M.L.
Gómez M.B.
Haad C.R.
Heffernan J.A.J.
Hernandez Marrero Domingo
Hernández A.F.
Hernández A.P.R.
Hernández M.R.
Hernández R.M.
Hernández S.B.
Hernández Á.A.
Herranz V.M.
Huerta E.L.
Huertas S.S.
Iglesias V.C.
Jacobs-Cachá C.
José R.M.S.
Jover A.S.
Juárez G.M.F.
Juárez J.R.
Lahuerta J.I.H.
Larrea C.L.
Lavilla F.J.
Lechuga J.A.
León M.
Llavona E.C.
Lopez-Díaz A.M.
Lourdes M.
Lucas M.F.
Luengas I.L.M.
Luis-Lima S.
López Hernández F.J.
López J.J.V.
López M.B.
López N.C.
López V.
López-Hoyos M.
Majoral J.S.
Mallen P.D.
Mallol L.L.
Malo A.M.
Maneus E.B.
Marchant V.
Marcos E.M.
Marimont M.B.
Mariño F.J.J.
Marqués M.
Marrah E.M.
Martin Orgaz Jose Manuel
Martin P.
Martos C.M.P.
Martín C.J.
Martín C.M.
Martín J.L.F.
Martín-Nuñez E.
Martínez Jiménez Victor
Martínez A.M.S.
Martínez C. M.
Martínez E.G.
Martínez J.M.C.
Martínez M.L.
Martínez S.M.S.
Masot N.D.
Matamoros O.B.
Mateo G.T.G.
Mateos F.J.M.
Mateos F.M.
Mateos S.R.
Mazuecos Auxiliadora
Melilli E.
Meneghini M.A.E.
Millán J.C.R.S.
Miranda D.M.
Miñambres Eduardo
Miñano J.A.P.
Molina M.C.
Molina Á.G.
Montero A.M.
Montes C.A.
Mora-Fernández M.D.C.
Morales Martín A.I.
Moreno Barón Marta
Moreno E.C.
Moreno I.D.D.
Moreno J.M.M.
Murias M.G.
Muñoz A.C.
Muñoz L.S.
Muñoz M.E.R.
Muñoz M.O.V.
Muñoz-Bellvis Luis
Nadah H.B.
Navarro-González J.
Oliva M.L.
Oliva M.R.
Oliveras X.F.
Olmo R.S.
Ongil S.L.
Ortega A.O.
Ortega M.R.
Ortiz Alberto
Ortiz M.E.R.
Ortiz P.J.C.
Ortiz P.S.
Pachón M.D.R.
Palacios A.M.C.
Panadés E.S.
Parra E.G.
Pavón F.G.
Pelaez S.L.
Pelicano J.M.B.
Peregrin C.M.
Perez Contreras Javier
Perez Tamajon M.L.
Peña H.G.
Pintor-Chocano A.
Piñeiro G.J.
Piñeiro P.B.
Plana J.M.C.
Porras A.B.
Porras L.F.Q.
Porrini E.
Portoles J.
Prado R.F.
Puyol D.R.
Pybus Marc
Pérez Bermúdez Pilar
Pérez M.P.
Pérez N.M.
Pérez-Aradros J.C.
Pérez-Gómez M.V.
Pérez-Monteoliva N.R.R.
Quiroga Borja
Ramos A.M.
Ramos S.A.
Ravassa F.O.V.
Rebollo G.
Rebollo M.S.G.
Redondo E.D.B.
Revilla J.M.V.
Ribagorda M.
Ribera A.T.
Rinne A.M.G.
Rituerto D.C.
Rivera J.R.
Rodiguez N.Z.
Rodrigues-Diez R.R.
Rodriguez Perez Jose Carlos
Rodriguez Mariano
Rodríguez C.D.
Rodríguez F.S.
Rodríguez G.G.
Rodríguez L.F.
Rodríguez M.L.
Rodríguez N.Z.
Rodríguez R.M.
Rodríguez S.G.
Roger Marta
Roig J.S.
Romeo Casabona Carlos Maria
Rosell M.N.S.
Rubio E.
Rubio M.A.B.
Ruiz P.
Saborido M.I.T.
Sagrario M.
Salgado C.M.
Salido J.A.
Salinas F.O.
Sanjuan A.E.
Sans Atxer Laia
Santos J.P.
Sanz A.B.
Saénz D.S.
Seara M.A.F.
Segundo D.S.
Serra C.R.
Serra Núria
Serrano B.M.
Serrano E.M.A.R.
Serres F.E.B.
Silva Irene
Sola E.
Sole L.C.
Soler Romeo Maria Jose
Soriano Cabrera Mª Sagrario
Sosa D.Á.
Stanojevic M.B.
Sáez M.J.P.
Sánchez Álvarez José Emilio
Sánchez F.P.
Sánchez S.P.
Sánchez-Niño M.D.
Sánchez-Rodríguez J.
Sánchez-Sobrino B.
Tamajon P.
Tamajón M.L.P.
Tejedor-Santamaria L.
Tejera-Muñoz A.
Tejero E.A.
Terente M.P.
Terroba Y.A.
Teruel J.L.G.
Tocados J.M.D.
Toro L.C.
Torra Balcells Roser
Torres A.
Torres Armando
Torres C.C.
Torres M.P.R.
Torres S.E.
Tortosa C.L.R.
Val M.H.
Valdemoros R.L.
Valero R.
Valiño-Rivas L.
Varela J.C.
Velázquez Á.S.
Verde A.M.R.
Vicente I.R.
Vicente L.V.
Vicente M. P.
Vila L.E.
Villalba I.L.
Villanueva R.S.
Villares J.M.P.
Virgala J.M.
Vázquez A.L.
Zamorano S.M.
Zelaya F.M.
Álvarez B.S.
Álvarez C.G.
Álvarez E.S.
Álvarez M.L.S.
Publication venue
Publication date: 01/01/2022
Field of study

Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is 'solved' by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020-2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Renal have now applied for the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true

Diposit Digital de Documents de la UAB

Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in Spain between March and November 2020: SEMI-COVID national registry

Author: Abad M.D.C.B.
Abanedes C.I.S.
Aizpuru E.M.F.
Alcalá J.N.
Alegría J.G.
Amezua C.H.
Amodeo Oblitas C.M.
Andreu M.D.M.G.
Antúnez M.G.
Arenzana C.B.
Aseguinolaza M.G.
Ayala-Gutiérrez M.M.
Ayuso B.
Bailón M.M.
Balaz D.
Bandera V.A.
Beamonte E.D.C.
Beato R.A.
Benbunan C.C.
Bengoa G.D.
Bermejo C.L.
Bermúdez M.
Blanco A.L.
Bueso T.S.
Buonaiuto V.A.
Caleya J.F.L.
Calvo C.M.
Campo B.M.
Candalija A.C.
Capitán C.F.
Carmona J.M.
Carracedo E.F.
Carrasco A.G.
Carrillo R.
Carvajal M.C.C.
Casado L.P.
Casanova P.C.
Casas L.A.
Casas-Rojo J.-M.
Castro S.M.
Cañas C.A.
Cebrián M.B.
Chamorro L.M.T.
Christophel A.T.F.-T.
Clotet N.C.
Corbella X.
Corral J.B.
Corral-Gudino L.
Cruz A.F.
Cuchillo J.B.
Cánovas J.S.
De Blas P.A.
De La Calle G.M.
De La Chica M.N.
De Luque C.M.C.
De Oña Á.A.
De Pedro I.P.
De Santos S.
De Windt F.
Del Pino J.L.
Delgado C.M.
Do Rego A.T.
Elías A.E.C.
Escalante M.D.M.
Escudero S.C.
Estrada A.D.B.
Etayo M.Z.
Fernandez-Bravo I.G.
Fernandez-Castelao S.
Fernández A.M.
Fernández F.A.
Fernández M.S.
Fernández P.C.
Fernández-Garcés M.
Fernández-Llamazares G.S.
Fonseca J.B.
Fontan P.M.P.
Fontán P.M.P.
Frías M.C.
Galeano Valle F.
Galvañ V.G.
Garcia A.
Garcia M.V.V.
García A.T.
García C.A.
García García G.M.
García J.G.
García S.L.
Gil C.R.H.
Godoy R.M.
Gonzalo J.L.
Gonzalo L.A.
Grela A.G.
Guerrero M.B.
Guillan E.M.P.
Gurjian A.A.
Gutiérrez J.C.M.
Gómez A.E.
Gómez C.R.
Gómez J.A.
Hernández A.L.
Hernández C.D.
Hernández M.J.J.
Homs N.
Hontañón V.
Huelgas R.G.
Huerta L.J.
Hurtado Oliver J.A.
Ibáñez L.J.
Iglesias M.F.G.
Iscar C.O.
Jansen-Chaparro S.
Jenaro M.M.F.-M.
Jimeno V.M.
Jiménez P.D.
Jiménez-García N.
Klepzig J.L.G.
Lahoz C.
Laorden C.J.
Ledesma S.M.
Leoni M.E.G.
Lezaun C.G.
Llorente B.P.
Lora-Tamayo J.
Lorenzo-Hernández E.
López C.M.O.
López I.B.
López M.M.M.
López M.N.
López R.B.
López-Carmona M.D.
Macías M.T.
Manau J.V.
Manglano J.D.
Manuel E.C.
Martínez D.L.
Martínez J.M.H.
Martínez L.F.C.
Martínez M.L.T.
Martínez R.F.-M.
Mayoral M.V.
Mendo C.L.
Mera I.F.
Molina S.C.
Montero A.
Montes J.T.
Mora-Luján J.M.
Morejón J.B.
Moreno A.D.C.
Moreno M.C.
Mozo A.N.
Murgui R.M.
Muriel C.C.
Muñoz B.G.
Muñoz E.C.
Muñoz J.A.
Míguez A.M.
Narciso C.G.S.
Nohales C.M.
Nuñez M.P.
Núñez-Cortés J.M.
Ocaña P.G.
Olleros C.L.
Ortega L.O.
Palacios L.C.
Pampyn M.P.
Pedroche C.D.
Peláez E.P.
Peralta E.E.D.
Perpiña B.O.
Pineda-Cantero A.
Prieto J.M.M.
Prieto M.M.
Purificación A.S.
Pérez S.C.
Pérez V.E.
Pérez-Belmonte L.M.
Quintana F.B.
Quirantes P.L.
Ramos J.C.
Reyne A.G.
Rhyman N.
Ricci M.
Rivera N.A.
Robles E.M.
Rodriguez V.N.
Rodríguez-Mancheño A.L.
Romero F.N.
Romero M.A.F.
Royo Trallero L.E.
Rubio-Rivas M.
Ruiz D.P.
Ruiz S.P.
Ruperto L.R.
Saavedra M.O.F.
Saldaña A.M.
Samaniego N.T.
Sampalo A.L.
Sanz M.T.M.
Sanz M.T.P.
Sevilla J.J.M.
Sierra J.O.
Simon R.D.
Simón M.A.Q.
Suárez A.M.Á.
Sánchez S.P.
Tabares Y.U.
Tejido S.C.
Torre R.S.
Troncoso J.Á.
Veganzones L.I.
Vergés C.D.
Vidal A.D.
Vieitez A.C.
Vilan L.D.
Villarreal G.
Virto A.P.
Wikman-Jorgensen P.E.
Yeguas I.A.
Zapico A.M.
Publication venue: 'MDPI AG'
Publication date: 01/01/2021
Field of study

Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID- 19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p < 0.001), with hypertension (57.0% vs. 47.7%; p < 0.001), obesity (26.4% vs. 19.3%; p < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; p < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7-160) vs. 49.3 (16-109) mg/dL; p < 0.001), ferritin (791 (393-1534) vs. 470 (236- 996) µg/dL; p < 0.001), D dimer (750 (430-1400) vs. 617 (345-1180) µg/dL; p < 0.001), and lower Sp02/Fi02 (266 (91.1) vs. 301 (101); p < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; p < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%. Conclusions: Patients with greater comorbidity, severity, and inflammatory markers were those treated with CTs. In severe patients, there is a trend towards the use of higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%

Repositorio Universidad de Zaragoza

Prospective cohort study of patients with COVID-19 hospitalized in the Internal Medicine ward of Hospital Durand: study protocol

Fil: Melendi, Santiago E. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Pérez, María M. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Salas, Cintia E. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Aguirre, Camila. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Baleta, María L. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Balsano, Facundo J. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Caldano, Mariano G. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Colignon, María G. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Oliveira Brasil, Thayana De. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Wolodimeroff, Nicolás de. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Déramo Aquino, Andrea I. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Fernández de Córdova, Ana G. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Fontan, María B. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Galvagno, Florencia I. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Haedo, Mariana F. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Iturrieta Araya, Noelia S. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Mollinedo Cruz,Volga S. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Olivero, Agustín. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Pestalardo, Ignacio. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Ricciardi, María. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Saltos Navarrete, Jandry D. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Vera Rueda, María L. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Villaverde, María C. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Xavier, Franco B. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Lauko, Marcela. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Ujeda, Carlos. Hospital General de Agudos Carlos G. Durand; Argentina.Fil: Leis, Rocío. Hospital General de Agudos Carlos G. Durand; Argentina.INTRODUCCIÓN: Conocer los predictores de mala evolución en pacientes con Enfermedad por Coronavirus 2019 (COVID-19) permite identificar de forma temprana a los pacientes con peor pronóstico, aportando mejores herramientas a la hora de tomar decisiones clínicas. Se presenta el protocolo de un estudio de cohorte cuyo objetivo principal es identificar factores de riesgo de infección severa, critica y mortalidad en pacientes con COVID-19 internados en el Servicio de Clínica Médica del Hospital Durand (Buenos Aires, Argentina). MÉTODOS: Estudio de cohorte prospectivo con base en un único centro. Se incluirá a todos los pacientes que ingresen al servicio de Clínica Médica con diagnóstico de COVID-19 durante el periodo de estudio. Se recolectarán las características epidemiológicas, clínicas, de laboratorio, radiológicas y los datos de tratamiento, al ingreso y al momento del alta o muerte hospitalaria. El evento final primario es la muerte en la internación; los eventos secundarios son el desarrollo de enfermedad grave y enfermedad crítica, la internación en unidad cerrada y el requerimiento de asistencia respiratoria mecánica

Sistema de Gestión del Conocimiento ANLIS MALBRÁN